Highlights

  • Oura faces a proposed US class action alleging misleading claims about the accuracy of its sleep-tracking technology.
  • The company disputes the allegations and maintains that its wearable technology is supported by scientific research.
  • Oura is expanding Health Radar and GLP-1 Insights into additional international markets.
  • The company postponed its proposed Nasdaq listing in September 2026, citing market uncertainty.

Oura, a privately held Finnish wearable technology company specialising in smart rings and biometric health monitoring, is facing legal scrutiny in the United States over claims relating to its sleep-tracking technology. The company has disputed the allegations while continuing to develop health monitoring features across its product portfolio.

The developments come after Oura postponed its planned Nasdaq initial public offering in September 2026, placing additional attention on its commercial strategy, product accuracy and future capital markets plans.

Oura Faces Legal Challenge Over Sleep-Tracking Claims

A proposed class action lawsuit was filed against Oura in the United States District Court for the Northern District of California on 20 August 2026.

The complaint, brought on behalf of purchasers of Oura smart rings, challenges the company's advertising claims concerning sleep-stage detection accuracy.

The allegations concern devices including Oura Ring 4, Ring 4 Ceramic and Ring 5.

The plaintiffs argue that conventional clinical sleep studies rely on direct measurements of brain activity, eye movements and muscle tone to identify different sleep stages.

Oura's devices instead use biometric measurements collected through sensors worn on the finger.

The complaint alleges that advertising claims concerning sleep-stage accuracy may misrepresent the relationship between these indirect measurements and clinical sleep assessment.

However, the allegations remain contested and have not been established as findings of wrongdoing by a court.

Oura Defends Its Wearable Health Technology

Oura maintains that its sleep-tracking technology is supported by scientific research and validation studies.

Chief medical officer Dr Ricky Bloomfield has defended the company's approach, emphasising the role of wearable technology in helping individuals better understand their health patterns.

Oura rings use photoplethysmography sensors, which measure changes in reflected light to estimate blood volume variations associated with heart activity.

Additional sensors monitor movement and skin temperature.

The company combines these signals through algorithms to estimate sleep duration, sleep stages and recovery-related information.

However, consumer wearable devices differ from clinical polysomnography, which directly measures neurological and physiological activity during sleep.

Oura's products are designed to provide health and wellness insights rather than replace clinical diagnostic examinations.

Health Radar Expands Cardiovascular and Respiratory Monitoring

Alongside the legal proceedings, Oura is expanding its Health Radar platform.

The feature builds on Symptom Radar, introduced in 2024, and incorporates additional cardiovascular and respiratory monitoring capabilities.

Health Radar includes Blood Pressure Signals, which evaluates overnight biometric patterns associated with cardiovascular health.

Rather than providing conventional systolic and diastolic blood pressure readings, the feature examines patterns that may warrant additional attention.

The platform also includes Nighttime Breathing, which provides a rolling 30-day assessment of sleep-related breathing patterns and disturbances.

These features are designed to help users identify changes in their health data and determine when professional medical assessment may be appropriate.

However, they are not substitutes for clinical blood pressure measurement or diagnostic testing for sleep disorders.

GLP-1 Insights Broadens Health Monitoring Applications

Oura has also introduced GLP-1 Insights, a feature designed for individuals using GLP-1 medications.

The tool allows users to record medication schedules, doses, side effects and weight changes alongside existing sleep, activity and recovery information.

By bringing these measurements together, the company aims to provide a longer-term view of changes in physiological and behavioural patterns.

The feature does not prescribe medication, recommend dosage adjustments or replace medical supervision.

On 6 October 2026, Oura announced the expansion of Health Radar and GLP-1 Insights into more than 30 additional markets, including Australia, New Zealand, the United Kingdom and European Union countries.

The rollout is intended to broaden access to the company's health-monitoring platform across international markets.

Nasdaq IPO Postponed Amid Market Uncertainty

Oura announced the postponement of its planned United States initial public offering on 29 September 2026.

The company cited uncertain market conditions as the reason for delaying the proposed transaction.

Chief executive Tom Hale indicated that Oura intended to pursue a public listing when conditions were more suitable.

The postponement followed preparations for a Nasdaq listing, which would have provided access to public equity markets.

However, the company has not announced a revised listing date.

As of 12 October 2026, Oura remains privately held and is not traded on the Australian Securities Exchange or Nasdaq.

Key Insights

Oura's ongoing legal proceedings highlight the importance of transparency around the capabilities and limitations of consumer health-monitoring technologies.

The company continues expanding its software platform through cardiovascular monitoring, respiratory insights and medication-related health tracking.

However, new features must be distinguished from clinically validated diagnostic capabilities.

As of 12 October 2026, significant developments include the progress of the US lawsuit, international feature expansion and any subsequent announcement concerning its postponed public listing.